Welcome to our dedicated page for DAXOR news (Ticker: DXR), a resource for investors and traders seeking the latest updates and insights on DAXOR stock.
Daxor Corporation (NASDAQ: DXR) is a medical instrumentation and biotechnology company focused on blood volume measurement, and its news flow centers on developments in this specialized diagnostic area. The company describes itself as the global leader in blood volume measurement technology, with approximately 50 years of experience and a patented, FDA-cleared Blood Volume Analysis (BVA) diagnostic platform.
News about Daxor frequently highlights regulatory milestones, such as FDA 510(k) clearance for its next-generation rapid, compact, hand-held, lab-based Blood Volume Analyzer (Daxor BVA™). Announcements also cover commercial expansion, including adoption of its BVA platform and ezBVA Lab Service by health systems, academic medical centers and cardiology practices, as well as deployments of on-site analyzers for immediate blood volume assessment.
Investors and clinicians following DXR can expect updates on clinical research that evaluates BVA-guided care in conditions like heart failure, LVAD implantation, cardiac amyloidosis, sepsis and COVID-19. Company releases summarize peer-reviewed studies and pilot trials that examine outcomes such as readmissions, survival, kidney injury and hospital length of stay when blood volume analysis is incorporated into care pathways.
Daxor’s news flow also includes participation in medical and investor conferences, where management presents corporate updates and showcases its technology to cardiovascular and critical care audiences, as well as institutional investors. For those tracking DXR, this news page offers a focused view of how the company’s blood volume analysis technology is progressing through regulatory clearance, clinical validation and market adoption over time.
Daxor Corporation (NYSE: DXR) recently presented findings from studies at the Heart Failure Society of America Annual Scientific Meeting, confirming the effectiveness of its BVA-100 blood test in managing heart failure. Research from Duke Heart demonstrated that traditional pressure metrics do not correlate with blood volume in heart failure patients. The BVA-100 offers 98% accuracy in blood volume measurement, providing crucial data for therapy optimization. This innovation is vital for enhancing patient outcomes and reducing healthcare costs, reassuring investors of Daxor's commitment to advancing heart failure management.
Daxor Corporation (Nasdaq: DXR) will present new patient outcome data at the Annual Scientific Meeting of the Heart Failure Society of America from September 30 to October 3, 2022, in Washington, DC. Key findings include significant reductions in heart failure readmissions (56%), 30-day mortality (82%), and 1-year mortality (86%) associated with blood volume analysis (BVA). This event will gather leading experts to discuss advancements in heart failure management. Daxor aims to improve healthcare through BVA technology, which has been validated by over 60,000 tests nationwide.
Daxor Corporation (Nasdaq: DXR) announces CEO Michael Feldschuh's participation at the H.C. Wainwright 24th Annual Global Investment Conference, scheduled for September 12-14, 2022, in New York. Attendees can request one-on-one meetings with him through the provided registration link. Daxor is renowned for its blood volume measurement technology, particularly the BVA-100®, enabling accurate quantification of blood volume, significantly improving patient outcomes. The company is involved in ongoing trials supported by the NIH, focusing on COVID-19 and heart failure treatment.
Daxor Corporation (Nasdaq: DXR), a leader in blood volume measurement technology, reported a 35.3% increase in net assets, totaling $19.6 million or $4.85 per share as of June 30, 2022. Despite a 7.3% decrease from year-end 2021, the operating division's valuation remained stable at $16.5 million. The company experienced a 92.6% revenue increase in its diagnostic segment, driven by sales and leasing of equipment. Furthermore, Daxor successfully completed a DOD contract for a portable blood volume analyzer, with anticipated FDA approval by Q4 2022, paving the way for a significant product launch.
Daxor Corporation (NYSE: DXR) reported a remarkable 92.6% revenue growth driven by the successful commercialization of its BVA-100® Blood Volume Analyzer. Significant factors include the launch of 12 new accounts, a 9.2% price increase, and orders from the U.S. Department of Defense. The firm also disclosed net assets of $19.6 million per share, rising 35.3% year-over-year. Furthermore, Daxor is progressing on a new portable blood volume analyzer with FDA submission expected by year-end, projecting a 2023 launch.
Daxor Corporation (Nasdaq: DXR) will announce its financial results for the six months ending June 30, 2022, on August 25, 2022, at approximately 4:00 p.m. ET. The earnings conference call will be hosted by President and CEO Michael Feldschuh and CFO Robert Michel at 4:30 p.m. ET on the same day. Investors can participate in a Q&A session by submitting their questions via email. The conference call will also be available through a live webcast, with replay options until November 25, 2022. Daxor is recognized for its innovative blood volume measurement technologies.
Daxor Corporation (Nasdaq: DXR) reported a 49.4% increase in year-over-year sales of its single-use diagnostic kits. The company also achieved a 10.4% growth in sales from Q1 to Q2 2022, benefitting from new accounts and increased capital equipment purchases. Recent successes include a major acquisition at a leading Illinois academic center and expansion within a major South Carolina healthcare organization servicing 1.5 million patients. Ongoing clinical studies and contracts with the U.S. military are not included in these figures but are contributing additional revenue.
Daxor (Nasdaq: DXR) has partnered with MedAxiom to enhance the adoption of its blood volume analysis (BVA) technology. This collaboration aims to improve patient outcomes, reduce healthcare costs, and optimize clinician experiences as heart failure diagnoses rise. Daxor's BVA technology has demonstrated significant improvements in patient metrics, including an 82% decrease in 30-day mortality and enhanced treatment plans with 98% accuracy. The partnership leverages MedAxiom's extensive network to accelerate technology delivery in the cardiovascular community, aligning with healthcare’s Quadruple Aim.
Daxor Corporation (Nasdaq: DXR) has secured funding from the National Institute of Health (NIH) to enhance its clinical decision support software aimed at improving heart failure treatment.
The company participated in the NIH's Innovation Corps (I-Corps™) program, which supports businesses ready for commercialization of NIH-funded projects. This program provided vital resources to accelerate the launch of Daxor’s software, designed to optimize fluid management in acute heart failure.
Daxor Corporation (Nasdaq: DXR) has entered a Cooperative Research and Development Agreement with The Uniformed Services University and The Henry M. Jackson Foundation. The collaboration aims to develop a non-nuclear blood volume diagnostic device, enhancing the existing BVA-100 technology. This device is designed for both military and civilian use, targeting conditions like trauma and heart failure. Extensive studies validate Daxor's technology, showing a potential for improved patient outcomes by significantly enhancing fluid management in critical care.